| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
87,080,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s compound, batoclimab, is a human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Co.'s product candidate, batoclimab, has been dosed in small volumes (e.g., two mL) and with a 27-gauge needle, while still generating therapeutically relevant pharmacodynamic activity. Co. is developing batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,526,316 |
1,977,983 |
| Total Buy Value |
$0 |
$0 |
$58,000,008 |
$60,700,210 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
4 |
| Total Shares Sold |
121,451 |
211,093 |
494,767 |
657,606 |
| Total Sell Value |
$3,709,409 |
$7,040,317 |
$13,330,723 |
$15,815,635 |
| Total People Sold |
7 |
10 |
10 |
10 |
| Total Sell Transactions |
16 |
30 |
46 |
72 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Salzmann Peter |
Chief Executive Officer |
• • – |
2023-01-11 |
4 |
S |
$16.80 |
$67,553 |
D/D |
(4,021) |
993,932 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2023-01-11 |
4 |
S |
$15.15 |
$75,525 |
D/D |
(4,510) |
268,347 |
|
- |
|
| Butchko Julia G. |
Chief Dev. & Tech. Officer |
• – – |
2023-01-11 |
4 |
S |
$15.16 |
$1,015,596 |
D/D |
(60,490) |
331,419 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2023-01-11 |
4 |
S |
$15.11 |
$746,317 |
D/D |
(44,568) |
263,533 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2022-10-21 |
4 |
S |
$9.67 |
$3,297 |
D/D |
(341) |
308,101 |
|
- |
|
| Butchko Julia G. |
Chief Dev. & Tech. Officer |
• – – |
2022-10-13 |
4 |
S |
$9.18 |
$8,519 |
D/D |
(928) |
391,909 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2022-10-13 |
4 |
S |
$9.18 |
$25,640 |
D/D |
(2,793) |
997,953 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2022-10-11 |
4 |
S |
$9.44 |
$118,000 |
D/D |
(12,500) |
272,857 |
|
- |
|
| Roivant Sciences Ltd. |
|
• • • |
2022-10-06 |
4 |
B |
$6.00 |
$2,500,002 |
D/D |
416,667 |
73,805,331 |
0.01 |
- |
|
| Pande Atul |
Director |
– • – |
2022-09-30 |
4 |
B |
$5.60 |
$84,000 |
I/I |
15,000 |
20,000 |
2.1 |
- |
|
| Torti Frank |
Director |
– • – |
2022-09-29 |
4 |
B |
$5.81 |
$116,200 |
D/D |
20,000 |
393,358 |
2.39 |
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2022-09-28 |
4 |
S |
$4.67 |
$7,495 |
D/D |
(1,605) |
1,000,746 |
|
- |
|
| Butchko Julia G. |
Chief Dev. & Tech. Officer |
• – – |
2022-09-28 |
4 |
S |
$4.67 |
$2,498 |
D/D |
(535) |
392,837 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2022-08-30 |
4 |
S |
$5.83 |
$9,585 |
D/D |
(1,644) |
1,002,351 |
|
- |
|
| Butchko Julia G. |
Chief Dev. & Tech. Officer |
• – – |
2022-08-30 |
4 |
S |
$5.83 |
$3,195 |
D/D |
(548) |
393,372 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
112,816 |
285,357 |
|
- |
|
| Hughes Douglas J. |
Director |
– • – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
21,059 |
101,232 |
|
- |
|
| Torti Frank |
Director |
– • – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
225,632 |
373,358 |
|
- |
|
| Migausky George V |
Director |
– • – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
21,059 |
109,985 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
112,816 |
308,442 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
451,264 |
1,003,995 |
|
- |
|
| Fromkin Drew J |
Director |
– • – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
21,059 |
88,485 |
|
- |
|
| Butchko Julia G. |
Chief Dev. & Tech. Officer |
• – – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
112,816 |
393,920 |
|
- |
|
| Levine Mark S. |
Chief Legal Officer |
• – – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
112,816 |
255,816 |
|
- |
|
| Pande Atul |
Director |
– • – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
21,059 |
82,985 |
|
- |
|
182 Records found
|
|
Page 4 of 8 |
|
|
